Latest Breaking News On - Serious adverse event - Page 8 : comparemela.com

Ryvu Therapeutics Reports First Quarter 2021 Financial Results News provided by Share this article Share this article KRAKOW, Poland, May 12, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU) reported today its first quarter 2021 financial results and provided a corporate update. Q1 2021 was an eventful quarter for Ryvu and developments around RVU120 played a key role in it - commented Pawel Przewiezlikowski, Chief Executive Officer of Ryvu. We have submitted a clinical trial application to conduct a Phase I/II study of RVU120 in patients with solid tumors, and shortly after that we received an approval to expand the ongoing Phase I of RVU120 in AML and high risk MDS from US sites to Poland. We have also secured a non-dilutive grant to finance the RVU120 solid tumor study. Despite the recent partial clinical hold imposed on RVU120 Phase Ib study, we have achieved meaningful research progress in our clinical and pre-clinical pipeline in these first months of 2021. Patient safet

United statesPawel przewiezlikowskiCentral ethics committeeNational centerDrug administrationAmerican association of cancer researchWarsaw stock exchangeStock exchange company of the yearDevelopment ncbiWarsaw stock exchange company of the yearOffice for registrationServices innovationOffice for registration of medicinal productsChief executive officerClinical trial applicationPolish office